文献速递胸部肿瘤

免疫检查点抑制剂在非小细胞肺癌中的获益-危害平衡

Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2025-01-01

该回顾性队列研究利用2013至2019年SEER-Medicare数据,纳入17681例66岁及以上非小细胞肺癌患者,比较ICI联合化疗与单药ICI的严重irAE和死亡风险。结果显示,一线ICI联合化疗较单药ICI增加严重irAE风险(HR 1.18),但降低死亡风险(HR 0.66);每延长1年生存,严重irAE风险增加0.31。

要点

  • 一线ICI联合化疗较单药ICI增加严重irAE风险(HR 1.18),但降低死亡风险(HR 0.66)。
  • 二线及以上ICI联合化疗较单药ICI未显著增加严重irAE风险(HR 1.04)或降低死亡风险(HR 0.94)。
  • 一线ICI联合化疗的获益-危害平衡在男性及无自身免疫病患者中也具统计学意义。

核心结论

  • 考虑治疗相关危害与获益,一线使用ICI联合化疗需知情决策;在高危亚组中,ICI联合化疗较单药ICI的潜在获益令人鼓舞。

研究设计与样本

  • 回顾性队列研究,使用2013至2019年SEER-Medicare数据,纳入17681例66岁及以上非小细胞肺癌患者,均暴露于任何ICI。
  • 暴露组为ICI联合化疗(3432例,19.4%)与单药ICI(14249例,80.6%,参照组)。

主要发现

  • 一线治疗中,ICI联合化疗组较单药ICI组严重irAE风险升高(HR 1.18;95%CI 1.06-1.30),死亡风险降低(HR 0.66;95%CI 0.62-0.72)。
  • 二线及以上治疗中,ICI联合化疗组较单药ICI组严重irAE风险无显著差异(HR 1.04;95%CI 0.92-1.19),死亡风险无显著差异(HR 0.94;95%CI 0.68-1.03)。
  • 一线治疗中,ICI联合化疗对有(vs无)基线自身免疫病患者延迟死亡更明显。
  • 每延长1年生存,严重irAE风险为0.31(95%CI 0.09-0.53),该权衡在男性及无自身免疫病患者中也具统计学意义。

临床怎么用

  • 一线使用ICI联合化疗需结合治疗相关危害与获益进行知情决策;高危亚组中ICI联合化疗较单药ICI的潜在获益令人鼓舞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The benefits and harms of immune checkpoint inhibitor (ICI) therapy for lung cancer vary across groups, including those typically underrepresented in randomized clinical trials. OBJECTIVE: To quantify the harms and benefits of ICI-containing regimens in individuals with non-small cell lung cancer and assess heterogeneity across priority subgroups. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study conducted in 2024 used 2013 to 2019 Surveillance, Epidemiology, and End Results (SEER) Medicare data of individuals 66 years or older with non-small cell lung cancer who were exposed to any ICI. EXPOSURES: ICI + chemotherapy, single ICI (reference group). MAIN OUTCOMES: Severe immune-related adverse events (irAE; harm) and mortality (when delayed mortality was the benefit). Severe irAEs were defined using validated diagnosis and medication codes. Mortality was ascertained from Medicare data. Hazard ratios (HRs) were estimated and 95% CIs were stratified by whether an ICI was used as the first or second or later systemic anticancer treatment (SACT) and in subgroups defined by preexisting autoimmune disease, sex, and age. The harm-benefit tradeoff was described as excess severe irAEs per year of life gained in which the gain in survival time was assessed using restricted mean survival time. RESULTS: Of 17 681 Medicare beneficiaries, 8797 (49.5%) were female, and the mean (SD) age was 74 (6.0) years. Compared with a single ICI (14 249 [80.6%]), individuals treated with ICI + chemotherapy (3432 [19.4%]) had an elevated risk of severe irAE in the first SACT setting (hazard ratio [HR], 1.18; 95% CI, 1.06-1.30) but not in the second or later SACT setting (HR, 1.04; 95% CI, 0.92-1.19); there was a decreased risk of mortality in the first SACT setting (HR, 0.66; 95% CI, 0.62-0.72) but not in the second or later SACT setting (HR, 0.94; 95% CI, 0.68-1.03). In the first SACT setting, ICI + chemotherapy delayed mortality more among patients with (vs without) autoimmune disease at baseline. For each 1 year of life gained, the risk of severe irAEs was 0.31 (95% CI, 0.09-0.53) and the tradeoff was also statistically significant in men and patients without autoimmune disease. CONCLUSIONS: The results of this cohort study suggest that given both treatment-related harms and benefits, ICI + chemotherapy use in the first SACT setting requires informed decision-making; the potential benefits of ICI + chemotherapy vs single ICI in high-risk subgroups is encouraging.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Heyward J, Lesko CR, Murray JC, et al. Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. JAMA Oncol. 2025. PMID: 40338588. doi:10.1001/jamaoncol.2025.0985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。